Arrowhead Pharmaceuticals recently received the FDA NDA acceptance for Plozasiran. Read why I believe ARWR stock could be a ...

IPO - Read IPO Review and Analysis on The Economic Times. Find out IPO Issue Price, Subscription Dates and Status, IPO Listing Date and more.

Sionna late Thursday said it is selling nearly 10.6 million shares at $18 apiece in the IPO, compared with prior plans to offer about 8.82 million shares at between $16 and $18 each. The Waltham, Mass ...

Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...

Clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis—Sionna Therapeutics (SION) priced its upsized initial public offering of ...

The gross proceeds from the initial public offering are expected to be approximately $191 million, before deducting underwriting discounts and commissions and other offering expenses, and excluding ...

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...

US private equity firm Riverwood Capital is buying Quicklizard for NIS 186 million, reflecting a 30% premium on yesterday's ...

Infinity Natural Resources was valued at $1.30 billion after its shares jumped nearly 11% in their NYSE debut on Friday, ...

Citi reduced its Kalyan Jewellers target price from Rs 810 to Rs 650, implying a return potential of 47.5% over Thursday's close.

Dr Agarwal's Healthcare: The IPO opens for subscription with an issue size of Rs 3,027.2 crore. Price band: Rs 382 to Rs 402 per share. Denta Water and Infra Solutions: To list on the exchanges after ...

The Arlington, Virginia-based firm on Wednesday slashed its price range by more than 40% to upper guidance of $65 billion, down from $110 billion. The revised IPO plan, first reported by Reuters ...